This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

A Study Of Implantation Of Retinal Pigment Epithelium In Subjects With Acute Wet Age Related Macular Degeneration

This study has suspended participant recruitment.
Sponsor:
Collaborator:
University College, London
Information provided by (Responsible Party):
Pfizer
ClinicalTrials.gov Identifier:
NCT01691261
First received: September 19, 2012
Last updated: January 4, 2017
Last verified: January 2017
September 19, 2012
January 4, 2017
June 2015
March 2017   (Final data collection date for primary outcome measure)
  • Incidence and severity of adverse events. [ Time Frame: 52 weeks ]
  • Change in baseline in ETDRS best corrected visual acuity (BCVA) - Proportion of subjects with an improvement of 15 letters or more at Week 24. [ Time Frame: 24 weeks ]
Same as current
Complete list of historical versions of study NCT01691261 on ClinicalTrials.gov Archive Site
  • Change in baseline in ETDRS best corrected visual acuity (BCVA) - Proportion of subjects with an impovement of 15 letters or more [ Time Frame: Weeks 1,2,4,8, 12,16, 36, 52 ]
  • Mean change of best corrected visual acuity (BCVA) from baseline by study visit. [ Time Frame: 52 weeks ]
  • Position of PF-05206388 by serial biomicroscopic evaluation. [ Time Frame: Day 2 and Weeks 1, 2, 4, 8, 10, 12, 16, 24, 36, 52 ]
  • Position and presence of pigmented RPE cells by serial fundus photography [ Time Frame: Weeks 2, 4, 8, 10, 12, 16, 24, 36, 52 ]
  • Mean change from baseline in contrast sensitivity by Pelli Robson test [ Time Frame: Weeks 24, 52 ]
  • Change in liver and renal function by blood tests and liver ultrasound . [ Time Frame: Weeks 24 and 52 ]
  • Change in leakage or perfusion in normal fundal vasculature and presence of abnormal vasculature by fundus fluorescein angiography. [ Time Frame: Weeks 4, 8, 12, 24 and 52 ]
  • Change in central 30 degree of visual function by Humphrey Field test. [ Time Frame: Weeks 4, 8, 12, 24 and 52 ]
  • Change in thickness of RPE layer by B-mode orbital ultrasound. [ Time Frame: Weeks 4, 8, 16, 24, 36, 52 ]
  • Change in baseline in ETDRS best corrected visual acuity (BCVA) - Proportion of subjects with an improvement of 15 letters or more [ Time Frame: at Weeks 1,2,4,8, 12,16, 36 & 52. ]
  • Mean change of best corrected visual acuity (BCVA) from baseline by study visit. [ Time Frame: 52 weeks ]
  • Position of PF-05206388 by serial biomicroscopic evaluation. [ Time Frame: at Weeks 1, 2, 4,8, 10, 12, 16, 24, 36 and 52 ]
  • Position and presence of pigmented Retinal Pigment Epithelium cells by serial fundus photography and SLO autofluorescence. [ Time Frame: at Weeks 4, 6, 10, 12, 16, 24, 36 and 52 ]
  • Placement of PF-05206388 by serial spectral domain Ocular CoherenceTomography (OCT) scan [ Time Frame: at Weeks 4, 8, 12, 16, 24, 36 and 52. ]
  • Change in liver and renal function by blood tests and liver ultrasound . [ Time Frame: at Weeks 24 and 52 ]
  • Change in leakage or perfusion in normal fundal vasculature and presence of abnormal vasculature by fundus fluorescein angiography. [ Time Frame: at Weeks 4, 8, 12, 24 and 52 ]
  • Change in central 30 degree of visual function by Humphrey Field test. [ Time Frame: at Weeks 4, 8, 12, 24 and 52 ]
  • Evidence of diffuse retinal and RPE toxicity by full field ERG and EOG. [ Time Frame: at Weeks 12 and 52 ]
  • Photoreceptor survival (indirect indication of RPE survival) by Adaptive Optics. [ Time Frame: at Weeks 16, 24, 36 and 52 ]
  • Functional survival of retinal photoreceptors by Nidekmicroperimetry over PF-05206388. [ Time Frame: at Weeks 4, 16, 36 and 52 ]
  • Change in reading speed by Minnesota (MN) Read test. [ Time Frame: at Weeks 4, 8, 16, 24, 36 and 52 ]
  • Change in thickness of RPE layer by B-mode orbital ultrasound. [ Time Frame: at Weeks 4, 8, 16, 24, 36 and 52 ]
  • Detection of alloactive T-cells and alloreactive antibodies (blood) . [ Time Frame: at Weeks 2, 4, 8 12, 24 and 52 ]
Not Provided
Not Provided
 
A Study Of Implantation Of Retinal Pigment Epithelium In Subjects With Acute Wet Age Related Macular Degeneration
Phase 1, Open-Label, Safety And Feasibility Study Of Implantation Of PF-05206388 (Human Embryonic Stem Cell Derived Retinal Pigment Epithelium (RPE) Living Tissue Equivalent) In Subjects With Acute Wet Age Related Macular Degeneration And Recent Rapid Vision Decline
Phase 1 trial of retinal pigment epithelium replacement in subjects with wet age-related macular degeneration in whom there is rapidly progressing vision loss
Phase 1, open-label, safety and feasibility study of implantation of PF-05206388 (human embryonic stem cell derived retinal pigment epithelium) in subjects with wet age related macular degeneration and rapid vision loss
Interventional
Phase 1
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Age Related Macular Degeneration
Biological: PF-05206388
PF-05206388 will be provided as a Retinal Pigment Epithelium living tissue equivalent for intraocular use in the form of a monolayer of Retinal Pigmented Epithelial (RPE) cells immobilized on a polyester membrane. The membrane is approximately 6 mm x 3 mm and will contain a confluent layer of RPE cells, at a nominal dose of 17 mm2. The implant is intended to be life-long.
Experimental: Treatment
PF-05206388 Retinal Pigment Epithelium living tissue equivalent for intraocular use in the form of a monolayer of Retinal Pigmented Epithelial (RPE) cells immobilized on a polyester membrane
Intervention: Biological: PF-05206388
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Suspended
10
March 2017
March 2017   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male and /or post-menopausal female subjects aged 60 years or above.
  • Diagnosis of wet Age-related Macular Degeneration (AMD) plus rapid recent vision decline
  • An informed consent document signed and dated by the subject or a legal representative.

Exclusion Criteria:

  • Pregnant females; breastfeeding females; and females of childbearing potential.
  • Treatment with an investigational drug within 30 days (or as determined by the local requirement, whichever is longer) or 5 half-lives preceding the first dose of study medication.
  • Current or previous significant other ocular disease in the study eye, as determined by the investigator.
Sexes Eligible for Study: All
60 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United Kingdom
 
 
NCT01691261
B4711001
2011-005493-37 ( EudraCT Number )
Yes
Not Provided
Not Provided
Pfizer
Pfizer
University College, London
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
January 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP